We’ve shown in previous studies that antibody-mediated neutralization of FABP4 improves metabolic health in obese mice by lowering hepatic glucose production, improving insulin sensitivity, and reducing hepatic steatosis (Prentice et al, 2021; Burak et al, 2015). The gene discussed is FABP4; the disease is Hepatic steatosis.